DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/pjkkrj/erythropoietin) has announced the addition of the "Erythropoietin Market in Japan 2015-2019" report to their offering.
The erythropoietin market in Japan to decline at a CAGR of (1.16) % over the period 2014-2019.
The report, Erythropoietin Market in Japan 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the landscape of the erythropoietin market in Japan and its growth prospects in the coming years. The report includes a discussion on the key vendors operating in this market. To calculate the market size, the report considers revenue generated from the sales of erythropoietin drugs and biosimilars used in the treatment of anemia due to renal disease, chemotherapy, antiretroviral therapy, wounds, or neurological conditions.
Biosimilars are more cost-effective than branded erythropoietin drugs. The favorable regulatory scenario in Japan increases the focus of pharmaceutical companies on the development of biosimilars. After the implementation of the new regulatory framework for biosimilars in March 2009, seven biosimilar products have been approved in the country.
In addition, patent expiries of branded biologics provide significant opportunities for vendors to develop their corresponding biosimilars. For instance, Epoetin alfa BS injection by JCR Pharmaceuticals and Kissei Pharmaceutical is a biosimilar form of epoetin alfa that was launched in the market in May 2010.
According to the report, kidney diseases, cancer, and HIV can cause anemia in people. The kidneys of individuals with chronic kidney disease do not function normally due to the decrease in the levels of erythropoietin. Such patients have a deficiency of iron, vitamin B12, and folic acid, which are essential for the formation of hemoglobin by red blood cells.
This leads to anemia in patients. The condition is aggravated in individuals with dysfunctional kidneys who require dialysis. About 80% of such individuals undergo erythropoietin therapy for the treatment of anemia. The Japanese Society for Dialysis Therapy reported that the number of people who require dialysis patients is increasing every year in the country.
Further, the report states that erythropoietin drugs are expensive and unaffordable to many people.
Key vendors
- Chugai Pharmaceutical
- JCR Pharmaceuticals
- Kissei Pharmaceutical
- Kyowa Hakko Kirin
Other prominent vendors
- Eisai
- Otsuka
- Taiho Pharmaceutical
- Takeda
For more information visit http://www.researchandmarkets.com/research/pjkkrj/erythropoietin
